Russo Alessia E, Ferraù Francesco, Antonelli Giovanna, Priolo Domenico, McCubrey James A, Libra Massimo
Department of Biomedical Sciences, Section of Pathology and Oncology, Laboratory of Translational Oncology and Functional Genomics, University of Catania, 85 Androne Avenue, Catania 95124, Italy.
Expert Rev Anticancer Ther. 2015 Jan;15(1):101-8. doi: 10.1586/14737140.2015.961426. Epub 2014 Sep 24.
Malignant melanoma is an aggressive tumor with a poor prognosis for patients with advanced disease. Over the last decades, its incidence and mortality has increased in elderly population, impacting significantly on healthcare costs, considering the increase in average age of the world population. Older age is recognized as an independent poor prognostic factor for melanoma, but the scientific community now is wondering if elderly melanoma patients have worse outcome because they are not receiving the same treatment as their younger counterparts. This article summarizes current data on elderly melanoma prevention and early detection and its subsequent management, underling the differences observed between older and younger patients. It also describes age-associated alterations in immunity and how these may impact on anti-melanoma response.
恶性黑色素瘤是一种侵袭性肿瘤，对于晚期疾病患者预后较差。在过去几十年中，考虑到世界人口平均年龄的增加，其在老年人群中的发病率和死亡率有所上升，对医疗成本产生了重大影响。老年被认为是黑色素瘤的一个独立不良预后因素，但科学界现在想知道老年黑色素瘤患者的预后是否更差，因为他们没有接受与年轻患者相同的治疗。本文总结了关于老年黑色素瘤预防、早期检测及其后续管理的当前数据，强调了老年患者和年轻患者之间观察到的差异。它还描述了与年龄相关的免疫改变以及这些改变如何影响抗黑色素瘤反应。
